On the evening of December 8, news on the official website of the State Food and Drug Administration showed that China's first independent intellectual property rights new coronavirus neutralizing antibody combination therapy drug was approved.

  On December 9, Luo Yongqing, the person in charge of the drug development company and CEO of Tengsheng Huachuang, said in an exclusive interview with a reporter from China News Agency that in order to develop the new crown neutralizing antibody ambavirumab/romisvirumab combination therapy, The enterprise has invested more than 1 billion yuan.

He introduced that after the drug is approved for marketing, he is currently negotiating with relevant departments, hoping that the drug can benefit patients as soon as possible.

(Reporter Xu Pengpeng)

Editor in charge: [Ji Xiang]